Anima Biotech Inc. has divulged collagen 1 (COL1) translation inhibitors reported to be useful for the treatment of cirrhosis, fibrosis, nonalcoholic or metabolic dysfunction-associated ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
This study presents valuable findings implicating nuclear export in the regulation of protein condensate behaviour and TDP-43 phase behaviour, suggesting a link to pathogenic aggregation in ALS/FTD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results